<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498119</url>
  </required_header>
  <id_info>
    <org_study_id>RG291-14AFR</org_study_id>
    <nct_id>NCT02498119</nct_id>
  </id_info>
  <brief_title>The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome</brief_title>
  <official_title>The Role of Arachidonic Acid Metabolites, in the Lipid Droplets of Macrophages From Patients With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an increase in lipid bodies in leukocytes
      will lead to an increase in eicosanoid production. The 2nd purpose is to determine if there
      is a significant correlation between lipid body formation and enhanced generation of both
      Lipoxygenase (LO) and COX derived eicosanoids. The 3rd purpose is, if lipid bodies are
      involved in arachidonic acid (AA) metabolism, then AA present in these lipid rich structure
      must be released by phospholipases and the free Arachidonic Acid (AA) must have access to the
      eicosanoid forming enzyme. The fourth objective is to determine the compartmentalisation of
      cPLA2 and MAP kinases including ERK1, ERK2, p85 and p38 are involved in AA liberation within
      lipid bodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome is a cluster of biochemical and physiological abnormalities associated
      with the development of cardiovascular disease and type 2 diabetes mellitus. The current
      study focused on type 2 Diabetes Mellitus(T2DM). T2DM is a chronic disease in which people
      have problems regulating their blood sugar. This disorder consists of an array of
      dysfunctions characterized by hyperglycemia and resulting from the combination of resistance
      of insulin action, inadequate insulin secretion and excessive or inappropriate glucagon
      secretion. Insulin resistance results from a complex interplay between nutrient overload,
      systemic fatty acid excess, inflammation of the adipose tissue, endoplasmic reticulum and
      oxidative stress.

      At the molecular lever, inflammatory cytokines, fatty acid derivatives such as ceramides,
      diacylglycerols and reactive oxygen species (ROS), activate several serine/threonine kinases,
      that have emerged as important negative regulators of insulin signaling. Because of their
      ability to directly oxidize DNA, protein and lipid damage, ROS are believed to play a key
      role in the metabolic syndrome and the possible development of T2DM. It is possible that ROS
      and oxidative stress, induced by elevations in glucose and possibly free fatty acid levels
      play a key role in causing insulin resistance, and beta cell dysfunction by their ability to
      activate stress sensitive signaling pathways.

      Lipids as signaling intermediates encompass a vast range of molecules with distinct function.
      The characteristics includes, lipid bodies(LB) are sites for the production of inflammatory
      mediators and LB within inflammatory cells contain arachidonyl lipids which serve as
      precursors for eicosanoids. In addition, formation of LB within inflammatory macrophages was
      positively correlated with augmented increase in prostaglandin E2 (PGE2) in changes. LB also
      could function as a draining compartment to rapidly uptake and re-acetylate free arachidonic
      acid with the potentially detrimental outcomes for the host cell.

      Macrophage from cells with lipid bodies involves complex and multi step mechanisms that
      depend on different signaling pathways regulating lipid influx, metabolism storage and
      mobilization. In view of these clues the investigators have reason to believe that organic
      anion transporters might be resident or upon stimulation trans located to lipid bodies in
      order to export the newly synthesized lipid mediators into the cytoplasmic space. Once
      outside the lipid bodies the eicosanoids can exert intracrine functions or be exported to
      plasma membrane resident transporters to the extracellular space. Free fatty acids have
      adverse effects on the mitochondrial function including uncoupling of oxidative
      phosphorylation and the generation of ROS. Beta cell lipotoxicity has an amplifying effect
      only if mediated by concurrent hyperglycemia. The association of obesity, fatty acids and
      oxidative stress with insulin action clearly merits further attention with particular focus
      on the molecular mechanism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Composite measure of patient physical observations to include weight, height and BMI</measure>
    <time_frame>six months only (1 time only)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of pro - inflammatory cytokines</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of eicosanoids in diabetic complication</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of LTB4 and LTC4 of eicosanoids</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>Patient sample within the normal range of blood results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abnormal</arm_group_label>
    <description>Patient sample from freshly diagnosed Type 2 Diabetes Mellitus.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood is collected and blood component separated for the future use. Whole blood, red
      blood cells, plasma and buffy coat are was separated and kept in -80 degree Celsius.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study subjects are recruited from Primary Care Clinic of University Malaya Medical
        Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 to ≤ 60

          -  Patient diagnosed with Type 2 Diabetes Mellitus within 1 year

        Exclusion Criteria:

          -  Patients &lt; 18 years

          -  Patients with uncontrolled diabetes, heart failure and sepsis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gracie Ong Siok Yan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Consultant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Komathi Perumal</last_name>
    <phone>6010-2114913</phone>
    <email>komathi_thesis@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Malaya Medical Center (UMMC)</name>
      <address>
        <city>Petaling Jaya</city>
        <state>Kuala Lumpur</state>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gracie Ong Siok Yan</last_name>
      <phone>019-3105617</phone>
      <email>gracieong@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Komathi Perumal</last_name>
      <phone>010-2114913</phone>
      <email>komathi_thesis@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <link>
    <url>http://jhc.sagepub.com/content/59/5/540.full.pdf+html</url>
    <description>Lipid bodies inflammatory cells: structure, function, and current imaging techniques</description>
  </link>
  <link>
    <url>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059578</url>
    <description>The internal architecture of leukocyte lipid body organelles captured by three-dimensional electron microscopy tomography</description>
  </link>
  <link>
    <url>http://www.jbc.org/content/277/46/44507.long</url>
    <description>The surface of lipid droplets is a phospholipid monolayer with a unique Fatty Acid composition</description>
  </link>
  <link>
    <url>http://www.jlr.org/content/52/12/2198.long</url>
    <description>Lipid body formation during maturation of human mast cells</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23740690</url>
    <description>Balancing the fat: lipid droplets and human disease</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21729000</url>
    <description>Is fat so bad? Modulation of endoplasmic reticulum stress by lipid droplet formation</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20303960</url>
    <description>a dynamic organelle moves into focus</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17878492</url>
    <description>The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis</description>
  </link>
  <link>
    <url>http://www.jbc.org/content/283/42/28005</url>
    <description>The gregarious lipid droplet</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19071229</url>
    <description>Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/6315820</url>
    <description>Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/6436254</url>
    <description>Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/8301140</url>
    <description>Differential roles for triglyceride and phospholipid pools of arachidonic acid in human lung macrophages</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/9502418</url>
    <description>Co-compartmentalization of MAP kinases and cytosolic phospholipase A2 at cytoplasmic arachidonate-rich lipid bodies</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/7595189</url>
    <description>Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19573621</url>
    <description>Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a monocyte chemotactic protein 1/ chemokine ligand 2 (MCP-1/CCL2) regulated phenomenon</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21565480</url>
    <description>Lipid body function in eicosanoids synthesis : An update</description>
  </link>
  <reference>
    <citation>Melo RC, D'Avila H, Wan HC, Bozza PT, Dvorak AM, Weller PF. Lipid bodies in inflammatory cells: structure, function, and current imaging techniques. J Histochem Cytochem. 2011 May;59(5):540-56. doi: 10.1369/0022155411404073. Epub 2011 Mar 23. Review.</citation>
    <PMID>21430261</PMID>
  </reference>
  <reference>
    <citation>Melo RC, Paganoti GF, Dvorak AM, Weller PF. The internal architecture of leukocyte lipid body organelles captured by three-dimensional electron microscopy tomography. PLoS One. 2013;8(3):e59578. doi: 10.1371/journal.pone.0059578. Epub 2013 Mar 26.</citation>
    <PMID>23555714</PMID>
  </reference>
  <reference>
    <citation>Tauchi-Sato K, Ozeki S, Houjou T, Taguchi R, Fujimoto T. The surface of lipid droplets is a phospholipid monolayer with a unique Fatty Acid composition. J Biol Chem. 2002 Nov 15;277(46):44507-12. Epub 2002 Sep 6.</citation>
    <PMID>12221100</PMID>
  </reference>
  <reference>
    <citation>Dichlberger A, Schlager S, Lappalainen J, Käkelä R, Hattula K, Butcher SJ, Schneider WJ, Kovanen PT. Lipid body formation during maturation of human mast cells. J Lipid Res. 2011 Dec;52(12):2198-208. doi: 10.1194/jlr.M019737. Epub 2011 Oct 4.</citation>
    <PMID>21971714</PMID>
  </reference>
  <reference>
    <citation>Krahmer N, Farese RV Jr, Walther TC. Balancing the fat: lipid droplets and human disease. EMBO Mol Med. 2013 Jul;5(7):973-83. doi: 10.1002/emmm.201100671. Epub 2013 Jun 6. Review.</citation>
    <PMID>23740690</PMID>
  </reference>
  <reference>
    <citation>Hapala I, Marza E, Ferreira T. Is fat so bad? Modulation of endoplasmic reticulum stress by lipid droplet formation. Biol Cell. 2011 Jun;103(6):271-85. doi: 10.1042/BC20100144. Review.</citation>
    <PMID>21729000</PMID>
  </reference>
  <reference>
    <citation>Beller M, Thiel K, Thul PJ, Jäckle H. Lipid droplets: a dynamic organelle moves into focus. FEBS Lett. 2010 Jun 3;584(11):2176-82. doi: 10.1016/j.febslet.2010.03.022. Epub 2010 Mar 18. Review.</citation>
    <PMID>20303960</PMID>
  </reference>
  <reference>
    <citation>Brasaemle DL. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J Lipid Res. 2007 Dec;48(12):2547-59. Epub 2007 Sep 18. Review.</citation>
    <PMID>17878492</PMID>
  </reference>
  <reference>
    <citation>Goodman JM. The gregarious lipid droplet. J Biol Chem. 2008 Oct 17;283(42):28005-9. doi: 10.1074/jbc.R800042200. Epub 2008 Jul 8. Review.</citation>
    <PMID>18611863</PMID>
  </reference>
  <reference>
    <citation>Blaner WS, O'Byrne SM, Wongsiriroj N, Kluwe J, D'Ambrosio DM, Jiang H, Schwabe RF, Hillman EM, Piantedosi R, Libien J. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim Biophys Acta. 2009 Jun;1791(6):467-73. doi: 10.1016/j.bbalip.2008.11.001. Epub 2008 Nov 24. Review.</citation>
    <PMID>19071229</PMID>
  </reference>
  <reference>
    <citation>Dvorak AM, Dvorak HF, Peters SP, Shulman ES, MacGlashan DW Jr, Pyne K, Harvey VS, Galli SJ, Lichtenstein LM. Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol. 1983 Dec;131(6):2965-76.</citation>
    <PMID>6315820</PMID>
  </reference>
  <reference>
    <citation>Dvorak AM, Hammel I, Schulman ES, Peters SP, MacGlashan DW Jr, Schleimer RP, Newball HH, Pyne K, Dvorak HF, Lichtenstein LM, et al. Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation. J Cell Biol. 1984 Nov;99(5):1678-87.</citation>
    <PMID>6436254</PMID>
  </reference>
  <reference>
    <citation>Triggiani M, Oriente A, Marone G. Differential roles for triglyceride and phospholipid pools of arachidonic acid in human lung macrophages. J Immunol. 1994 Feb 1;152(3):1394-403.</citation>
    <PMID>8301140</PMID>
  </reference>
  <reference>
    <citation>Yu W, Bozza PT, Tzizik DM, Gray JP, Cassara J, Dvorak AM, Weller PF. Co-compartmentalization of MAP kinases and cytosolic phospholipase A2 at cytoplasmic arachidonate-rich lipid bodies. Am J Pathol. 1998 Mar;152(3):759-69.</citation>
    <PMID>9502418</PMID>
  </reference>
  <reference>
    <citation>Triggiani M, Oriente A, Seeds MC, Bass DA, Marone G, Chilton FH. Migration of human inflammatory cells into the lung results in the remodeling of arachidonic acid into a triglyceride pool. J Exp Med. 1995 Nov 1;182(5):1181-90.</citation>
    <PMID>7595189</PMID>
  </reference>
  <reference>
    <citation>Silva AR, Pacheco P, Vieira-de-Abreu A, Maya-Monteiro CM, D'Alegria B, Magalhães KG, de Assis EF, Bandeira-Melo C, Castro-Faria-Neto HC, Bozza PT. Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon. Biochim Biophys Acta. 2009 Nov;1791(11):1066-75. doi: 10.1016/j.bbalip.2009.06.004. Epub 2009 Jun 30.</citation>
    <PMID>19573621</PMID>
  </reference>
  <reference>
    <citation>Bozza PT, Bakker-Abreu I, Navarro-Xavier RA, Bandeira-Melo C. Lipid body function in eicosanoid synthesis: an update. Prostaglandins Leukot Essent Fatty Acids. 2011 Nov;85(5):205-13. doi: 10.1016/j.plefa.2011.04.020. Epub 2011 May 12. Review.</citation>
    <PMID>21565480</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Gracie Ong @ Gracie Ong Siok Yan</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>Type 2 DM</keyword>
  <keyword>lipid bodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

